Table 1.
Baseline characteristics among patients with bioprosthetic valves or history of valve repair treated with apixaban or warfarin
| Characteristic | Apixaban(N = 87) | Warfarin(N = 69) | P‐value |
|---|---|---|---|
| Age, median (25th, 75th), years | 72 (63, 79) | 74 (65, 78) | 0.5088 |
| Female sex, no. (%) | 34 (39.1%) | 27 (39.1%) | 0.9949 |
| BMI, median (25th, 75th), kg/m2 | 26 (24, 31) | 27 (24, 32) | 0.3879 |
| Prior stroke, TIA, or SE, no. (%) | 24 (27.6%) | 12 (17.4%) | 0.1333 |
| LVEF, no. (%) | 0.7243 | ||
| Normal | 50 (58.8%) | 41 (62.1%) | |
| Mild dysfunction | 18 (21.2%) | 12 (18.2%) | |
| Moderate dysfunction | 10 (11.8%) | 10 (15.2%) | |
| Severe dysfunction | 7 (8.2%) | 3 (4.5%) | |
| Diabetes, no. (%) | 19 (21.8%) | 17 (24.6%) | 0.6803 |
| Hypertension, no. (%) | 68 (78.2%) | 64 (92.8%) | 0.0121 |
| Coronary artery disease, no. (%) | 36 (41.4%) | 32 (46.4%) | 0.5319 |
| Prior MI, no. (%) | 16 (18.4%) | 10 (14.5%) | 0.5164 |
| Heart failure, no. (%) | 30 (34.5%) | 24 (34.8%) | 0.9688 |
| Prior bleeding, no. (%) | 25 (28.7%) | 19 (27.5%) | 0.8687 |
| History of falls, no. (%) | 4 (4.9%) | 3 (4.9%) | 1.0000 |
| Type of AF, no. (%) | 0.9123 | ||
| Paroxysmal | 17 (19.5%) | 13 (18.8%) | |
| Non‐paroxysmal | 70 (80.5%) | 56 (81.2%) | |
| HAS‐BLED score, no. (%) | 0.8891 | ||
| 0–1 | 24 (27.6%) | 18 (26.1%) | |
| 2 | 32 (36.8%) | 28 (40.6%) | |
| ≥3 | 31 (35.6%) | 23 (33.3%) | |
| CHADS2 score, no. (%) | 0.3008 | ||
| ≤1 | 31 (35.6%) | 18 (26.1%) | |
| 2 | 26 (29.9%) | 28 (40.6%) | |
| ≥3 | 30 (34.5%) | 23 (33.3%) | |
| Chronic renal disease, no. (%) | 3 (3.5%) | 5 (7.2%) | 0.4681 |
| eGFR, median (25th, 75th) | 65 (55, 86) | 68 (47, 83) | 0.6376 |
| NT‐proBNP, median (25th, 75th), ng/L | 707 (448, 1159) | 826 (404, 1177) | 0.8198 |
| Concomitant medication, no. (%) | |||
| Aspirin | 24 (27.6%) | 25 (36.2%) | 0.2479 |
| Clopidogrel | 2 (2.3%) | 2 (2.9%) | 1.0000 |
| Digoxin | 29 (34.5%) | 23 (34.3%) | 0.9800 |
| ACE inhibitor or ARB | 68 (78.2%) | 53 (76.8%) | 0.8410 |
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; SE, systemic embolism; TIA, transient ischemic attack.